Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA + decitabine + venetoclax maintenance in non-transplant AML
ChiCTR2400086497Phase 4Not yet recruiting
- Sponsor
- Third People's Hospital of Chengdu
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tretinoin, decitabine and venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Third People's Hospital of Chengdu. Primary endpoint: 1-year recurrence-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tretinoindecitabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400086497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086497.